Gosse J. Adema
YOU?
Author Swipe
View article: Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration
Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration Open
Introduction Many immunotherapies focus on (re)invigorating CD8+ T cell anti-cancer responses. Different nuclear imaging techniques have been developed to measure CD8+ T cell distributions. Comprehensive comparisons of in vivo and ex vivo …
View article: ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer
ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer Open
Despite the availability of multiple effective therapies for localized prostate cancer, many patients still progress to incurable metastasized castration resistant prostate cancer (mCRPC). About 23 % of mCRPC patients carry alterations in …
View article: Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases
Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases Open
[This corrects the article DOI: 10.3389/fimmu.2024.1439413.].
View article: Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b+ dendritic cells and macrophages
Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b+ dendritic cells and macrophages Open
View article: Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment Open
Cancer-associated fibroblasts (CAFs) represent a group of genotypically non-malignant stromal cells in the tumor micro-environment (TME) of solid tumors that encompasses up to 80% of the tumor volume. Even though the phenotypic diversity a…
View article: Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation
Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation Open
Conclusion: Overall, this review offers guidance for the clinical implementation of combining M-HIFU with ICI and highlights key questions that remain to be addressed in first clinical studies.
View article: Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8<sup>+</sup>T-cell infiltration
Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8<sup>+</sup>T-cell infiltration Open
Many immunotherapies focus on (re)invigorating CD8 + T cell anti-cancer responses and different nuclear imaging techniques have been developed to measure CD8 + T cell distributions. In vivo labeling approaches using radiotracers primarily …
View article: Inhibition of OXPHOS induces metabolic rewiring and reduces hypoxia in murine tumor models
Inhibition of OXPHOS induces metabolic rewiring and reduces hypoxia in murine tumor models Open
View article: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases
The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases Open
Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals from cytokines and chemokines. Central to th…
View article: Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial Open
This trial of dual ICIs in molecularly selected mCRPC met its primary endpoint, showing DCR > 6 in 38% of patients. Dual ICIs exhibited modest responses in the hTMB, BRCAm, and CDK12i subgroups, but demonstrated exceptional efficacy in dMM…
View article: Siglec‐7 and Siglec‐9 expression in primary triple negative and oestrogen receptor positive breast cancer and <i>in vitro</i> signalling
Siglec‐7 and Siglec‐9 expression in primary triple negative and oestrogen receptor positive breast cancer and <i>in vitro</i> signalling Open
Objectives PD‐1/PD‐L1 immune checkpoint blockade can be an effective treatment for advanced breast cancer patients. However, patients with oestrogen receptor positive (ER+) tumors often display only low lymphocyte infiltration, while a lar…
View article: MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells
MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells Open
View article: Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells Open
The tumor microenvironment of glioblastoma IDH-wildtype is highly immune suppressive and is characterized by a strong component of myeloid-derived suppressor cells (MDSCs). To interfere with the immune suppressive functions of MDSCs, a com…
View article: MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1
MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1 Open
Introduction Combined radiotherapy and immune checkpoint inhibition is a potential treatment option for head and neck squamous cell carcinoma (HNSCC). Immunocompetent mouse models can help to successfully develop radio- immunotherapy combi…
View article: Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function
Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function Open
The T cell is an immune cell subset highly effective in eliminating cancer cells. Cancer immunotherapy empowers T cells and occupies a solid position in cancer treatment. The response rate, however, remains relatively low (<30%). The ef…
View article: Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging
Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging Open
Background Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a therapeutic strategy to reduce hypoxia. How…
View article: Radiotherapy induces an increase in serum antioxidant capacity reflecting tumor response
Radiotherapy induces an increase in serum antioxidant capacity reflecting tumor response Open
These data pertain to 2 publications on the effect of tamoxifen and irradiation on ROS and antioxidants. Earlier, we reported that tamoxifen-resistant (TAM-R) breast cancer cells are cross-resistant to irradiation. In PMID: 36755288, we in…
View article: Additional file 1 of Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer
Additional file 1 of Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer Open
Additional file 1: Figure S1. No difference in OCR or ECAR was detected between the WT and TAM-R cells or with acute tamoxifen treatment.
View article: Saponin-based adjuvants enhance antigen cross-presentation in human CD11c<sup>+</sup> CD1c<sup>+</sup> CD5<sup>−</sup> CD163<sup>+</sup> conventional type 2 dendritic cells
Saponin-based adjuvants enhance antigen cross-presentation in human CD11c<sup>+</sup> CD1c<sup>+</sup> CD5<sup>−</sup> CD163<sup>+</sup> conventional type 2 dendritic cells Open
Background Adjuvants are key for effective vaccination against cancer and chronic infectious diseases. Saponin-based adjuvants (SBAs) are unique among adjuvants in their ability to induce robust cell-mediated immune responses in addition t…
View article: Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7
Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7 Open
Tumors create an immunosuppressive tumor microenvironment by altering protein expression, but also by changing their glycosylation status, like altered expression of sialoglycans. Sialoglycans are capped with sialic acid sugar residues and…
View article: Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Figure from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
View article: Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors Open
Supplementary Data from Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors